A group of Researchers at Imperial College London created a molecule that can successfully block multiple strains of the common cold by targeting a protein required for the survival of the virus. The newly created molecule (IMP-1088) resides inside a protein in cells called N-myristoyltransferase (NMT). After invading the body, virus uses NMT to construct a shell for protecting their genomes, allowing them to replicate easily. Inhibiting the NMT with the molecule IMP-1088 restricted the growth and functioning of multiple strains of cold virus. According to the reports IMP-1088 has successfully blocked common cold virus without affecting the healthy cells. Team is planning to take IMP-1088 into animal trials to ensure that it is safe and does not target other conditions with different causes. Also, the team is now working on the drug delivery method via the lungs.
DelveInsight Blog
Related Article

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval
FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...
Find More
Top 7 Pharma Industry Leaders in 2020 By the Numbers
Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...
Find More
Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome’s Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks
Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca Samsung Biologics announced the conclusion of a long-term supply deal with AstraZeneca worth USD 330.8 Million. AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. H...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.